||Recombinant Human IGFBP4 (Accession # AAA62670) Asp22-Glu258, fused with an N-terminal Met, was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in PBS.
||Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF-7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.The ED50 for this effect is typically 0.03-0.09 µg/mL in the presence of 14 ng/mL recombinant human IGF-II.
||Recombinant Human IGFBP4, Met-tagged has a calculated MW of 26 kDa. In SDS-PAGE migrates as 32 kDa, reducing conditions.
||>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).